NCT05611268View on ClinicalTrials.gov

Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 3, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2026

Conditions
Eisenmenger Syndrome
Interventions
DRUG

Pentoxifylline

Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days

Trial Locations (1)

Unknown

RECRUITING

Antonio Augusto Barbosa Lopes, São Paulo

All Listed Sponsors
collaborator

InCor Heart Institute

OTHER

lead

University of Sao Paulo General Hospital

OTHER